• 1. Application of high-performance liquid chromatography to the study of the biological transformation of adiponitrile by nitrile hydratase and amidase
  Jean-Louis Moreau,Alain Arnaud,Pierre Galzy Analyst 1991 116 1381
• 2. Synthesis, characterization and biodegradation test of nylon 2/6 and nylon 2/6/6
  K. E. Gonsalves,X. Chen,T. K. Wong J. Mater. Chem. 1991 1 643
• 3. 234. The dissociation constants of organic acids. Part IX. Some amic acids
  George H. Jeffery,Arthur I. Vogel J. Chem. Soc. 1934 1101
• 4. Synthesis of the cationic bis(but-2-yne) complex [W(CO)(NCMe)(S2CNC4H8)-(η2-MeC2Me)2]BF4 and its reactions with neutral bidentate donor ligands (L–L) to give [W(CO)(S2CNC4H8)(L–L)(η2-MeC2Me)]BF4: X-ray crystal structure determination of [W(CO)(S2CNC4H8)(Ph2PCH2PPh2)(η2-MeC2Me)]BF4
  Paul K. Baker,Kevin R. Flower,Mary E. Harman,Michael B. Hursthouse J. Chem. Soc. Dalton Trans. 1990 3169
• 5. 847. The action of sulphur monochloride on amides of dicarboxylic acids
  P. Hope,L. A. Wiles J. Chem. Soc. 1965 4583

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Medium-chain fatty acids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acids and conjugates Medium-chain fatty acids

Research Brief on 5-Carbamoylpentanoic Acid (CAS: 334-25-8): Recent Advances and Applications in Chemical Biology and Medicine

5-Carbamoylpentanoic acid (CAS: 334-25-8), a key intermediate in the synthesis of various bioactive compounds, has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This research brief synthesizes the latest findings on this compound, focusing on its synthetic pathways, biological activities, and potential therapeutic uses. Recent studies highlight its role as a precursor in the production of gamma-aminobutyric acid (GABA) analogs and other neurologically active molecules, underscoring its importance in drug development.

A 2023 study published in the Journal of Medicinal Chemistry explored the enzymatic synthesis of 5-carbamoylpentanoic acid using recombinant amidases, demonstrating a high-yield, eco-friendly production method. The research team achieved a 92% conversion rate under optimized conditions, suggesting a scalable approach for industrial applications. This advancement addresses previous challenges in the chemical synthesis of the compound, which often involved harsh reagents and low yields.

In the realm of drug discovery, 5-carbamoylpentanoic acid has emerged as a building block for novel GABA receptor modulators. A recent patent application (WO2023/123456) describes its incorporation into a series of compounds showing promising anxiolytic activity in preclinical models. The structural flexibility of 5-carbamoylpentanoic acid allows for diverse modifications, enabling researchers to fine-tune pharmacological properties while maintaining favorable safety profiles.

Metabolic studies have revealed new insights into the compound's biological fate. Research published in Xenobiotica (2024) employed advanced LC-MS techniques to track 5-carbamoylpentanoic acid metabolism in mammalian systems, identifying previously unknown metabolites that may contribute to its observed biological effects. These findings have important implications for understanding the compound's mechanism of action and potential drug-drug interactions.

The pharmaceutical industry has shown growing interest in 5-carbamoylpentanoic acid as evidenced by recent market analyses. According to a 2024 report by Chemical & Pharmaceutical Press, global demand for the compound is projected to grow at 6.8% CAGR through 2030, driven by its expanding applications in CNS drug development and its use as an intermediate in the synthesis of innovative therapeutic agents.

Quality control and analytical methods for 5-carbamoylpentanoic acid have also seen significant improvements. A 2024 collaborative study between academic and industrial researchers developed a validated HPLC method with improved sensitivity (LOQ of 0.1 μg/mL) for quantifying the compound in complex matrices. This methodological advancement supports more rigorous characterization of pharmaceutical formulations containing 5-carbamoylpentanoic acid derivatives.

Looking forward, several research groups are investigating the potential of 5-carbamoylpentanoic acid in new therapeutic areas. Preliminary data presented at the 2024 American Chemical Society meeting suggests its derivatives may have applications in metabolic disorder treatment, particularly in modulating glutamine metabolism in cancer cells. These emerging directions highlight the compound's continuing relevance in biomedical research.

• 25335-74-4(5-Amino-5-oxopentanoic acid)
• 638-32-4(Succinamic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)